A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Clinical trial NCT06097663 · COMPLETED
Trial details
- NCT number
- NCT06097663
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-15
- Primary completion
- 2024-10-27
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.